

Modelling the role of immunity in reversion of viral antigenic sites

Carmen H. S. Chan^{a,b,*}, Lloyd P. Sanders^{a,b,c}, Mark M. Tanaka^{a,b}

^a*School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia*

^b*Evolution & Ecology Research Centre, University of New South Wales, Sydney, NSW, Australia*

^c*Computational Social Science, ETH, Zürich, Switzerland*

Abstract

Antigenic sites in viral pathogens exhibit distinctive evolutionary dynamics due to their role in evading recognition by host immunity. Antigenic selection is known to drive higher rates of non-synonymous substitution; less well understood is why differences are observed between viruses in their propensity to mutate to a novel or previously encountered amino acid. Here, we present a model to explain patterns of antigenic reversion and forward substitution in terms of the epidemiological and molecular processes of the viral population. We develop an analytical three-strain model and extend the analysis to a multi-site model to predict characteristics of observed sequence samples. Our model provides insight into how the balance between selection to escape immunity and to maintain viability is affected by the rate of mutational input. We also show that while low probabilities of reversion may be due to either a low cost of immune escape or slowly decaying host immunity, these two scenarios can be differentiated by the frequency patterns at antigenic sites. Comparison between frequency patterns of human influenza A (H3N2) and human RSV-A suggests that the increased rates of antigenic reversion in RSV-A is due to faster decaying immunity and not higher costs of escape.

Keywords: viral evolution, antigenic selection, back mutation, cost of escape, epidemiological model

1. Introduction

Viral evolution is shaped by both epidemiological effects on population dynamics, and molecular effects of mutations in the viral genome [1]. The combination of these effects generates distinctive dynamics at antigenic sites of viral proteins, which are the targets of host immune recognition. Selection for strains carrying antigenic changes that evade immune recognition result in elevated rates of non-synonymous substitution. It is unclear, however, why different dynamics of forward or reverse substitution are observed. Antigenic reversion has been reported frequently in viruses such as HIV [2, 3, 4], respiratory syncytial virus (RSV) [5] and hepatitis C [6, 7], and less frequently in other viruses such as influenza [8, 9], parvovirus [10], hepatitis A [11] and polio [12]. Various explanations for occurrence of reversion have been proposed, such as changing immunity [5], a limited antigenic repertoire [5, 9], or constraints on function [11, 7, 8], but it is not understood how the relative influence of these effects can generate differences in observed rates of reversion.

*Corresponding author

Email address: chschan@gmail.com (Carmen H. S. Chan)

12 The difficulty in evaluating the contribution of selective mechanisms is due to the lack of methods that model
13 both epidemiological and molecular dynamics. Phylodynamic approaches [13] incorporating epidemiological
14 models into a coalescent framework have provided insight into the origins and spread of novel pathogens.
15 However, they assume that molecular changes do not affect epidemiological dynamics, and are uninformative
16 about selection. In contrast, codon-based approaches [14, 15] aim to identify sites that contribute to the
17 adaptation of a virus, but they assume that the population size is constant and that the selection coefficient
18 is constant at each site. Various modifications of the substitution model allow for different selective effects
19 based on directionality or target residue [16, 2], but retain the assumption that substitution occurs as a time-
20 homogeneous process which is not affected by population dynamics. To understand how the probability of
21 reversion at antigenic sites is affected by both selective constraint against molecular changes and selection to
22 evade immune recognition, there is a need to incorporate the time-dependence imposed by epidemiological
23 dynamics into the substitution process.

24 Models of pathogen dynamics have shown that reversion probabilities are affected by fitness costs [17, 18,
25 3, 19], at both the within-host and between-host level, and the availability of susceptible hosts [3], at the
26 between-host level. However, these models were developed in the context of HIV escape mutations. HIV
27 infects host chronically, with host susceptibility determined by human leukocyte antigen (HLA) type, which
28 does not vary over time. Due to these infection dynamics the prevalence of each strain changes relatively
29 slowly, and is expected to eventually stabilise [3]. In contrast, for acute infections such as human influenza and
30 RSV where transmission occurs frequently and host immunity can last for much longer than the duration of
31 the infection, the structure of host immunity can vary rapidly over time. Due to differences in the dynamics of
32 selection, we expect antigenic selection to have qualitatively different effects on sequence changes at antigenic
33 sites compared to constant selective pressure [1].

34 Here, we examine the probability of antigenic reversion in an epidemiological model, which describes the
35 complex ecology of multiple viral strains with cross-immunity competing for susceptible hosts. This model
36 allows us to quantify the relative advantage of an antigenically novel mutation, compared to a reversion which
37 may be antigenically less advantageous, but improves transmission. Using both a simple three-strain model and
38 simulations with multiple codon sites, we examine the effect of the duration of host immunity, selective costs,
39 population size, and the basic reproductive ratio. We show that these effects lead to distinctive dynamics in
40 the frequencies of derived amino acids, which is informative about the duration of host immunity and strength
41 of selective constraint. Time-structured sequence data from influenza and RSV are compared to simulated
42 sequences, and we discuss what these results imply about the relative effects of host immunity and functional
43 constraint.

44 2. Methods

45 2.1. Simple analytical model for antigenic reversion

46 The simplest model containing reversion is a system where the population has mutated away from the
 47 ancestral state, and potentially can mutate either back to the ancestral state (reversion) or to a novel state
 48 (forward substitution). In an epidemiological context, we consider a viral population described by a three-
 49 strain SIRS model [20]. The viral population is initially of strain 0 (ancestral state), which is then replaced
 50 with strain 1, and can subsequently be replaced by either strain 0 (reversion) or strain 2 (forward substitution).

51 We assume a large host population of constant size N , with homogeneous mixing, so that the dynamics
 52 of the number of hosts which are susceptible S_i , infected I_i , and recovered with immunity R_i , for strains
 53 $i = 0, 1, 2$ can be described by

$$\frac{dI_i}{dt} = \beta_i \frac{S_i}{N} I_i - \delta I_i, \quad (1)$$

$$\frac{dR_i}{dt} = \delta I_i - \gamma R_i, \quad (2)$$

54 with transmission rate β_i , recovery rate δ , and immunity that decays at rate γ . Interactions between strains
 55 are described by the implicitly defined term S_i , which is the number of hosts susceptible to strain i . Assuming
 56 that each host can only be infected by a single strain at a time, and prior infection with strain j reduces
 57 susceptibility to strain i by a factor σ_{ij} , the relationship between susceptible and immune hosts is given by

$$S_i = N - \sum_j I_j - \sum_j \sigma_{ij} R_j, \quad (3)$$

58 with the constraint that $S_i > 0$ for any strain i . All uninfected hosts ($N - \sum_j I_j$) can be categorised as either
 59 susceptible (S_i) or immune ($\sum_j \sigma_{ij} R_j$) to strain i . The similarity between this model and the status-based
 60 model with polarised immunity developed by Gog and Grenfell [21] becomes evident when we differentiate
 61 Equation (3) to give

$$\begin{aligned} \frac{dS_i}{dt} &= - \sum_j \left(\frac{dI_j}{dt} + \sigma_{ij} \frac{dR_j}{dt} \right), \\ &= - \sum_j \beta_j \frac{S_j}{N} I_j + \sum_j \delta (1 - \sigma_{ij}) I_j + \sum_j \gamma \sigma_{ij} R_j. \end{aligned} \quad (4)$$

62 The main difference is that we retain the history of infections accumulated across the population through
 63 the additional set of variables, R_i . This allows us to obtain analytical expressions for the number of hosts
 64 susceptible to all strains as functions of the same set of variables, as shown in Equation (3). In contrast to the
 65 Gog and Grenfell [21] model assuming polarised immunity, we assume a model of partial additive immunity.
 66 A host that was infected twice with strain i at times t_1 and t_2 will contribute $r = \sigma_{ii} e^{-\gamma(t-t_1)} + \sigma_{ii} e^{\gamma(t-t_2)}$ to
 67 R_i at time t . This additive structure can be easily generalised to incorporate multiple strains. However, our
 68 model allows a host to contribute $r > 1$ after multiple re-infections, so we tend to inflate R_i . The effect of this
 69 approximation is examined in greater detail for a single strain system in Appendix A.1. Overall, the effect

70 of the approximation is to reduce I , but leave S unchanged. The approximation also tends to have minimal
71 effect when σ is small, or when the rate of immune decay varies between hosts.

72 Our model of partial additive immunity generates similar dynamics to the Gog and Grenfell model [21].
73 From Equation (4), it can be seen that hosts infected with strain j are removed from the susceptible class S_i ,
74 and then a proportion $1 - \sigma_{ij}$ of all infected hosts are returned to the susceptible class on recovery, so that
75 the overall contribution of immunity is $\sigma_{ij}\beta_j S_j I_j / N$, which is similar to the $\sigma_{ij}\beta_j S_i I_j / N$ term in the Gog and
76 Grenfell [21] model. The difference in the S_i and S_j term arises because in the Gog and Grenfell [21] model,
77 immunity arises from exposure, but in our model, immunity is only generated when infection occurs.

78 The strict exclusion of co-infection involves a second approximation, where an infection by any strain j
79 will always be removed from S_i but not from R_i [first term in Equation (4)]. This occurs because while it is
80 possible to distinguish between S_i and R_i at the time of infection from strain j , it is not possible, at the time
81 of recovery from strain j , to determine whether the host was previously susceptible or immune to strain i .
82 Our approximation leads to an underestimation of S_i . We expect this to have a small effect as the bias lasts
83 only for the duration of the infection. In addition, strains which are closest to the current circulating strain j
84 will not be heavily affected ($\sigma_{ij} \approx 1$); the most heavily affected strains are those distant from strain j which
85 are likely to be no longer circulating.

86 Using this model, we examine the effect of cross-immunity σ_{ij} , immunity duration γ and selective costs
87 incurred by antigenic escape s . The rate of immune decay γ includes the loss of immunity by the death
88 and migration of immune hosts as well as the loss of immunity in individual hosts. The selective cost is
89 parametrized through a reduction in the strain-specific transmission rate so that $\beta_0 = \beta$, $\beta_1 = \beta(1 - s)$ and
90 $\beta_2 = \beta(1 - s)^2$. To understand the effect of these parameters, we first characterise the number of susceptible
91 hosts to each strain at equilibrium, and use this to determine probabilities of fixation, assuming a single strain
92 appears at a time.

93 We assume the population is initially infected with only strain 0, which is maintained at equilibrium until
94 strain 1 emerges at time t_1 . Strain 1, then replaces strain 0 and equilibrates until time t_2 , when a third strain
95 (either strain 0 or strain 2) emerges and can potentially replace strain 1. These equilibrium assumptions
96 allow us to characterise host immunity accumulated due to infection by strain 0 at t_1 (denoted R_0^*), and host
97 immunity accumulated due to infection by strain 1 at t_2 (denoted R_1^*), which then allows us to evaluate the
98 probability of strain 0 or 2 emerging at time t_2 .

99 The equilibrium is obtained by setting the derivative of S_i and I_i to zero. When the viral population
100 consists of only one strain, the endemic equilibrium, which is asymptotically, locally stable when the basic
101 reproductive ratio $\beta_i/\delta > 1$ [20], is given by

$$S_i^* = \frac{\delta}{\beta_i} N, \quad (5)$$

$$I_i^* = \frac{\gamma N}{\delta\sigma_{ii} + \gamma} \left(1 - \frac{\delta}{\beta_i}\right). \quad (6)$$

102 We assume that at time t_1 , when strain 1 emerges, the population remains close to equilibrium. As strain

103 1 has only just emerged and strain 2 has not yet occurred, the cross-immunity terms in Equation (3) can be
 104 ignored so that it contains only terms of subscript $i = 0$. Substitution of Equations (5) and (6) into Equation
 105 (3) gives

$$R_0^* = \frac{\delta N}{\delta\sigma_{00} + \gamma} \left(1 - \frac{\delta}{\beta_0}\right). \quad (7)$$

106 Now, consider a later time t_2 , when a third strain (either 0 or 2) emerges and can potentially replace strain 1.
 107 Again, we assume that strain 1 remains close to equilibrium and that the third strain has had negligible effect
 108 on immunity. In addition, we assume that immunity due to infection by strain 0 has decayed exponentially
 109 since time t_1 , so that Equation (3) can be approximated as

$$S_1^* = N - I_1^* - \sigma_{11}R_1^* - \sigma_{10}R_0^*e^{-\gamma(t_2-t_1)}. \quad (8)$$

110 Substituting Equations (5) and (6) into (8) then gives

$$R_1^* = \frac{\delta N}{\delta\sigma_{11} + \gamma} \left(1 - \frac{\delta}{\beta_1}\right) - \frac{\delta\sigma_{10}N}{\sigma_{11}(\delta\sigma_{00} + \gamma)} \left(1 - \frac{\delta}{\beta_0}\right) e^{-\gamma(t_2-t_1)}. \quad (9)$$

111 Having obtained an expression for R_0^* and R_1^* , we can now compute the proportion of hosts that are susceptible
 112 to each strain, $p_i(\tau) = S_i(\tau)/N$, where $\tau = t_2 - t_1$ is the time since the emergence of strain 1. Thus,

$$p_0(\tau) = 1 - \frac{I_1^*}{N} - \frac{\sigma_{01}}{N}R_1^* - \frac{\sigma_{00}}{N}R_0^*e^{-\gamma\tau}, \quad (10)$$

$$p_2(\tau) = 1 - \frac{I_1^*}{N} - \frac{\sigma_{21}}{N}R_1^* - \frac{\sigma_{20}}{N}R_0^*e^{-\gamma\tau}, \quad (11)$$

113 which can be written in the form

$$p_i(\tau) = A + B_i e^{-\gamma\tau}, \text{ for } i = 0, 2. \quad (12)$$

114 Assuming that cross-immunity is additive with respect to the number of antigenic differences ($\sigma_{ii} = \sigma$, $\sigma_{01} =$
 115 $\sigma_{10} = \sigma_{21} = \sigma/2$ and $\sigma_{20} = 0$), the coefficients simplify to

$$A = 1 - \frac{\delta\sigma + 2\gamma}{2(\delta\sigma + \gamma)} \left(1 - \frac{\delta}{\beta_1}\right), \quad (13)$$

$$B_0 = -\frac{3\delta\sigma}{4(\delta\sigma + \gamma)} \left(1 - \frac{\delta}{\beta_0}\right), \quad (14)$$

$$B_2 = \frac{\delta\sigma}{4(\delta\sigma + \gamma)} \left(1 - \frac{\delta}{\beta_0}\right). \quad (15)$$

116 Note that we expect that prior immunity reduces infection against an unmutated strain at appreciable levels
 117 ($\sigma \gg 0.1$) and that immunity lasts for much longer than the infection duration ($\gamma \ll \delta$). Within the parameter
 118 range of interest, the fractional terms containing δ , σ and γ in Equations (13–15) approach constants, so that
 119 A is approximately a function of only β_1/δ and B_0 and B_2 are approximately functions of only β_0/δ .

120 We calculate the probability of a strain generated by reversion or forward mutation at time t_2 giving rise
 121 to a new epidemic by approximating the emergence of a new strain as a linear birth-death process. Ignoring
 122 initial changes in host susceptibility, the probability that a new strain reaches fixation [22] is given by

$$f_i = \begin{cases} 1 - \frac{1}{r_{e,i}}, & \text{if } r_{e,i} > 1 \\ 0, & \text{otherwise} \end{cases} \quad (16)$$

123 where $r_{e,i} = \beta_i p_i / \delta$ denotes the effective reproductive ratio of the new strain i at the time of emergence. Using
 124 Equations (12–15), at time τ after strain 1 has reached equilibrium, we compute the probability of fixation for
 125 strain 0 (reversion) and strain 2 (forward substitution) to be

$$f_i(\tau) = \begin{cases} 1 - \frac{\delta}{\beta_i(A+B_i e^{-\gamma\tau})}, & \text{if } \tau > t_{c,i} \\ 0, & \text{otherwise} \end{cases} \quad (17)$$

126 where the threshold $t_{c,i}$ is given by

$$t_{c,i} = \begin{cases} -\frac{1}{\gamma} \log \left(\frac{\delta}{\beta_0 B_0} - \frac{A}{B_0} \right), & \text{if } i = 0 \\ 0, & \text{if } i = 2 \end{cases} \quad (18)$$

127 The probability of reversion given fixation is therefore

$$\rho(\tau) = \frac{f_0(\tau)}{f_0(\tau) + f_2(\tau)}. \quad (19)$$

128 The probability of reversion is low immediately after the strain 0 has been replaced; in fact from Equations
 129 (17–19), it is zero for $\tau < t_{c,0}$. Asymptotically, if all prior immunity against strain 0 has decayed, then the
 130 exponential term in the denominator of Equation (17) approaches zero, thus giving

$$\rho_\infty = \frac{\beta_0 A - \delta}{2\beta_0 A - \delta(1 + \frac{\beta_0}{\beta_2})} \quad (20)$$

$$= \frac{\frac{1}{2} \left[\frac{\beta}{\delta} - (1-s)^{-1} \right] - 1}{\frac{\beta}{\delta} - (1-s)^{-1} - (1-s)^{-2} - 1}. \quad (21)$$

131 In summary, Equation (19) describes the combined effect of immunity γ and functional constraint s on the
 132 probability of reversion at some time τ after immunity has begun to wane from equilibrium levels. Whereas
 133 the long-term asymptote ρ_∞ , given by Equation (21), shows the effect of functional constraint in the absence
 134 of immunity.

135 2.2. Multi-site simulation model

136 To verify our theoretical model, and to examine the impact of increasing the antigenic space, we develop
 137 a stochastic computer simulation model where each infection is associated with a sequence of antigenic sites.
 138 Population dynamics are similar to the analytical model (see Table 1 for a complete list of parameters), but
 139 in the multi-site simulation, we explicitly model the mutation process. In the analytical model, we assumed
 140 the emergence of three strains at specified times, and calculated the probability that these strains would reach
 141 fixation. In contrast, for the simulation model, we allow mutations to occur stochastically at any antigenic
 142 site throughout the simulation; thus, new strains may emerge before the old strain reaches equilibrium and
 143 even favourable mutations may be lost due to stochasticity.

144 We implement two models using different representations of the antigenic space. The first model uses a
 145 bit-string representation so that each of the L_a antigenic sites can take values of $\mathbf{v} = \{0, 1\}$, and a change at
 146 any site away from the ancestral state (0) will reduce transmissibility. The bit-string model with two sites

147 has a antigenic space similar to the analytical model. In the second model, we use a more realistic codon
148 representation. Sites can mutate to any one of the 64 possible codons, but viral fitness is only affected by
149 non-synonymous changes (i.e., \mathbf{v} consists of the 20 amino acids). Specifically, any amino-acid change will affect
150 cross-immunity, but only changes from the ancestral amino acid to a derived state will reduce transmissibility.
151 The ancestral codon sequence is determined at the beginning of each simulation by randomly sampling L_a
152 non-terminating codons with uniform probability.

153 Throughout the simulation, we track the number of infected hosts I , the genotype of each infection, and the
154 immune status of the host population. The last variable is stored in the immunity matrix consisting of $2 \times L_a$
155 elements for the bit-string model, or $20 \times L_a$ for the codon model, where each element $r_{v,j}$ stores the number
156 of people with immunity to a value of v at site j . That is, $r_{v,j}$ stores the site-specific immunity accumulated
157 across the whole population, and we compute the immunity against any viral genotype by summing across
158 these values (described below).

159 The multi-site model is implemented as a discrete time simulation [22], with a time-step of one day. The
160 system is initialised with a naive population ($r_{v,j} = 0$ for all v and j) and an infected host which carries the
161 ancestral strain. At each time-step, the population changes according to SIRS dynamics, with the following
162 events occurring:

- 163 1. Mutation: The number of mutations that occur in the viral population in each time-step is drawn from
164 a Poisson distribution with mean μL_a , where μ is the mutation rate per site per time-step, and occur
165 uniformly across all sites and all individuals. For the codon model, the probability of any codon occurring
166 at the mutated site is specified by the Kimura two-parameter model [23] with a transition-transversion
167 rate of $\kappa = 3$.
- 168 2. Transmission: The number of potential new infections which occur in each time-step is a Poisson random
169 variable $X \sim \text{Pois}(\Lambda)$, where $\Lambda = \sum_{i=1}^I \beta(1-s)^{k_i}$ is the force of infection. The scaling factors $(1-s)^{k_i}$
170 account for the reduction in transmission of genotype i due to the cost of k_i changes away from the
171 ancestral strain. The genotypes of the X potential infections are determined by multinomial sampling
172 according to $(1-s)^{k_i}$, to account for variation in transmissibility within the viral population. We can
173 then calculate the probability of each potential infection i encountering a susceptible host, given by

$$p_i = \frac{N - I - \frac{\sigma}{L_a} \sum_{j=1}^{L_a} r_{v_{ij},j}}{N}, \quad (22)$$

174 where $r_{v_{ij},j}$ is the level of recognition against a particular antigenic site as described above. Equation
175 (22) corresponds to Equations (10–11) in the analytical model. The success of the potential infection is
176 determined using a Bernoulli random variable $U \sim \text{Bernoulli}(p_i)$. If $U = 1$, a new infection is generated
177 with a genotype identical to the parent.

- 178 3. Recovery: The number of infected hosts which recover in each time-step is Poisson with mean δI trun-
179 cated with an upper bound of $I - 1$. Each recovered host i is drawn from the infected population with

180 uniform probability and increases immunity to allele v_{ij} at site $j = 1, \dots, L_a$. That is, for each recovery,
181 we update L_a elements of the immunity matrix

$$r_{v_{ij},j} := r_{v_{ij},j} + 1. \quad (23)$$

182 4. Decay of host immunity (across the whole population) is simulated by reducing $r_{v,j}$ for all antigenic
183 states $v \in \mathbf{v}$ at each site $j = 1, \dots, L_a$ by a binomial random variable,

$$r_{v,j} := r_{v,j} - V, \text{ where } V \sim \text{Binom}(r_{v,j}, \gamma). \quad (24)$$

184 Note that the epidemic is artificially prevented from extinction. The forcing mechanism is necessary as we
185 have, for simplicity, not included a migration term. In stochastic models of recurrent epidemics, the infection
186 frequently dies out without re-introduction by migration, particularly in smaller populations [24, 25].

187 3. Results

188 Using the analytical and simulation models, we examine how the epidemiology of the virus affects the
189 probability of reversion at antigenic sites. We first describe the dynamics of the simple three-strain model
190 (Section 3.1), before examining the time dependence of this system (Section 3.2) and the effect of the epidemi-
191 ological parameters (Section 3.3). The combined effect of these interacting factors on the observed amino acid
192 frequencies is described in Section 3.4, and we compare this to sequence data for human influenza A (H3N2)
193 and RSV-A in Section 3.5.

194 3.1. Dynamics of changing susceptibility

195 To provide some intuition about the process, we show an example of forward substitution and reversion in
196 the three-strain model (Figure 1). The dynamics of the simulations, where mutations occur stochastically, are
197 compared to the analytical model by setting t_1 and t_2 to the times at which the strains are observed to emerge
198 in the simulation. By analogy with the three-strain model, whichever strain that emerges first containing one
199 mutation (either 01 or 10) is denoted strain 1. For the time interval shown here, only three strains emerge,
200 but over longer durations, all four strains will typically be observed.

201 For two separate simulations using the two-site bit-string model, we show the number of hosts infected
202 with each strain $i = 0, 1, 2$ [panels (a) and (b)], and the corresponding proportion of susceptible hosts p_i
203 [panels (c) and (d)]. The emergence of the ancestral strain 0 in the initially naive population sharply reduces
204 the proportion of susceptible hosts to strain 0, p_0 ; p_1 is also slightly reduced due to cross-immunity between
205 strains 0 and 1, while p_2 is unaffected. When strain 1 emerges and dominates the population, both p_0 and p_2
206 are temporarily reduced but p_0 slowly increases above its previous equilibrium.

207 In the first simulation [panels (a) and (c)], strain 1 is rapidly replaced with strain 2, so that at the time
208 of emergence t_2 , susceptibility to strain 0 remains quite low [black line in panel 1(c)]. In this case, forward
209 substitution is favoured because there is a larger pool of susceptible hosts for strain 2. In contrast, in panels

210 (b) and (d), the interval between t_1 and t_2 (vertical grey lines) is longer than the first simulation, providing
211 time for p_0 to reach similar levels to p_2 so that reversion can occur.

212 3.2. Time-dependence of the probability of reversion

213 In Figure 2, we show the probability of reversion as a function of $\tau = t_2 - t_1$, the interval between the
214 time of strain emergence (indicated by vertical grey lines in Figure 1). The theoretical probability of reversion
215 [Equation (19)] is compared to the proportion of reversion events in simulations with a two-site bit-string
216 model. We compute a proportion by binning substitution events with the same value of $\log_{10}(\tau)$, rounded to
217 two significant figures.

218 To correspond to the analytical model, only substitution events following transitions between strain 0 to
219 strain 1 are counted. Note that in the analytical model, τ is the interval between the times of emergence;
220 however, in the simulation, it is difficult to determine which of the emerging mutations will reach fixation. As
221 a proxy for τ , the counts from the simulation are binned according to the time between antigenic substitutions
222 (i.e. the time at which a different antigenic strain becomes the dominant strain in the population).

223 These results confirm that the reversion probability varies with τ . The probability of reversion is low if
224 substitution occurs rapidly, and gradually increases with τ until it flattens at the asymptote ρ_∞ , given by
225 Equation (21). This asymptotic value represents the probability of reversion in the absence of cross-immunity.
226 The decay rate of host immunity γ affects the speed at which the asymptotic value is reached, but not the
227 value of the asymptote.

228 Greater variation is seen in the simulated results for large τ , as these represent proportions computed from
229 a smaller number of more rare events. However, the greatest discrepancy between theoretical and simulated
230 results occurs near the transition $t_{c,0}$ [Equation (18)]. At $\tau = t_{c,0}$, the theoretical model predicts a sharp
231 transition away from $\rho(\tau) = 0$; in the stochastic simulations, the transition is more gradual. The reason for
232 this discrepancy is that the theoretical model assumes that each strain reaches equilibrium before it is replaced.
233 However, in large viral populations, the mutational input rate can be large enough that strain 1 replaces strain
234 0 before I_0 can reach equilibrium. In these cases, R_0^* will be upwardly biased, so that $\rho(\tau)$ underestimates the
235 probability of reversion. We confirm this in Figure B10 in Appendix B where a similar plot is shown ignoring
236 substitution events that occur before equilibrium is reached.

237 Based on the form of $\rho(\tau)$, we expect the time-dependent probability to be independent of the viral mutation
238 rate and population size. Consistent with this, we observe that simulation results for different population sizes
239 lie on the same curve, with points from small populations (circles) corresponding to large values of τ and
240 points from larger populations (triangles) corresponding to smaller values of τ .

241 3.3. The effect of epidemiological parameters

242 To examine the effects of viral transmission (β , δ , s) and host immunity (γ , σ), we now consider ρ for
243 a fixed τ in the analytical model [Equation (19)]. For simplicity of notation, we omit the argument τ in
244 this section. Equations (13–15) indicate that the strength of immune protection σ affects ρ only through the

245 coefficients A , B_0 , B_2 , and is expected to have only a weak effect. In Figure 3, we confirm that the level of
246 immune protection σ has only a weak effect on ρ unless the typical duration of the infection $1/\delta$ [Figure 3(a)]
247 is as long as the immune duration $1/\gamma$ [Figure 3(b)], or σ is negligibly small. Throughout the rest of the paper,
248 we set $\sigma = 1.0$.

249 Figure 4(a) shows how the reversion probability varies as a function of the basic reproductive ratio β/δ , for
250 various values of selective cost s , for a fixed level of host immunity ($\gamma\tau$). For sites under no selective constraint
251 (black line), the probability of reversion increases slightly with β/δ , but very different effects are observed
252 for a non-zero selective cost. The effect of a selective cost is strongest for small transmission rates, as slight
253 decreases in infection rates can have a more detrimental impact on the mutant subpopulation.

254 The interaction between the selective cost s , and the immunity decay rate γ , is shown for a fixed τ
255 [Figure 4(b)]. We showed in Figure 2 that for large $\gamma\tau$, $\rho(\tau)$ plateaus at ρ_∞ , which is independent of γ ;
256 however, when the rate of strain replacement is comparable to the decay rate of host immunity, there are
257 strong dependencies. The effect of varying γ , in the absence of selective constraint ($s \approx 0$), can be seen in the
258 difference between ρ where the curves plateau. Further increases in selective cost leads to a rapid increase in
259 the probability of reversion, with more rapid increases for longer lasting immunity (solid line).

260 3.4. Fluctuating frequencies at antigenic sites

261 In Sections 3.1–3.3, we observed that τ had a strong effect on whether reversions occur or not. In fact,
262 where τ is known, no further information on mutation rate μ or population size N is required. However, in
263 practice this quantity is difficult to measure. It is possible to account for variation in τ by integrating over the
264 distribution of τ , but this can remove important information; under certain parameter ranges, the stochasticity
265 of τ is sufficient to cause noticeable variation in reversion probabilities.

266 To observe the effect of fluctuations in ρ , we measure the frequency of the ancestral allele π_0 at each
267 antigenic site. The frequency of an allele is informative about its fixation probability [26], and the rate of
268 change in frequency is proportional to the strength of selection s [27, 17]. Under directional selection, we expect
269 any allele to eventually reach fixation or extinction. Thus fluctuations between $\pi_0 = 0$ to $\pi_0 = 1$ indicates
270 changes in selection. We measure the frequencies of each antigenic site separately, as immunity against each
271 site may vary depending on the history of previous circulating strains.

272 In Figure 5, we show frequency trajectories π_0 , under conditions of both antigenic selection and selective
273 constraint, so that antigenic changes away from the ancestral sequence imposes a cost. To account for in-
274 accuracies due to sampling, π_0 was computed from sequences sampled at discrete intervals, and the earliest
275 sequence sampled after the burn-in period was used as the ancestral sequence. In all panels, we observe fluctu-
276 ations in frequency levels as reversion probabilities vary due to the stochasticity of the time between antigenic
277 substitutions, although there is no change in μ , N , or s during a simulation. The pattern of fluctuations in π_0
278 differs depending on the host population size N (varying along columns) or the decay rate of host immunity
279 γ (varying along rows). Faster changes in π_0 are observed for larger N and fixation of the ancestral allele
280 becomes less likely. Tracking frequency over time also provides information on γ that would not be available

281 in the time-averaged approach. Comparison between columns in Figure 5 indicates that increasing γ tends to
282 reduce both the frequency and amplitude of π_0 . This effect is particularly evident for larger population sizes
283 [panels (c)–(f)], where the rate of substitution is not limited by the rate of mutational input.

284 The effect of removing the selective cost ($s = 0$) is shown in Figure 6. Although fluctuations can still
285 occur, the ancestral allele at the antigenic site rarely returns to fixation ($\pi_0 = 1$) and, if so, does not remain
286 fixed for long. This effect occurs even for small population sizes [panel (a)] which favour reversion. Continual
287 antigenic selection drives further substitutions to other derived amino acid residues, that have not induced
288 prior immunity. That is, multiple instances of increasing π_0 as an indication of high selective costs s is robust
289 to misspecification of the ancestral allele. However, consistently low values of π_0 may simply be due to using
290 an misspecified ancestral allele (an alternative interpretation is that π_0 correctly identifies that an unfavoured
291 amino acid is unconstrained).

292 3.5. Application to influenza and RSV

293 In Figure 7, we show π_0 changing over time for the human influenza A virus subtype H3N2 and the
294 respiratory syncytial virus (RSV) subtype A at antigenic and non-antigenic sites. The H3N2 data set consists
295 of all HA sequences for human H3N2 from the influenza virus database [28] where the year of sampling is
296 known. The accession numbers surface G protein sequences of RSV-A sequences that we used were listed
297 in Botosso et al. [5]. In total, we analysed 5831 H3N2 sequence spanning 45 years and 538 RSV sequences
298 spanning 19 years.

299 We computed π_0 for antigenic sites which have been identified by experimental methods, as sequence-based
300 methods are also designed to identify sites with variation in amino acid composition. For H3N2, we used the
301 seven sites (145, 155, 156, 158, 159, 189, 193) listed in a recent study [29] which used antigenic cartography
302 which integrates information over multiple pairs of antigen and antisera in order to evaluate overall antigenic
303 change [30]. For RSV-A, experimental studies with monoclonal antibodies have identified a large number
304 of sites which react to different monoclonal antibodies [31, 32]. More recent studies have used phylogenetic
305 analysis of natural isolates to identify potential antigenic sites [33, 34]. Note that there is an ascertainment
306 bias in using sites identified on the basis of frequent amino acid changes. Here, we have restricted the analysis
307 to eight sites (225, 226, 233, 237, 244, 274, 280, 290) which were identified as reducing antigenic recognition
308 in multiple studies [33, 34, 31, 32], with at least one being experimental [31, 32]. Including a larger number of
309 sites does not affect the results, but will obscure features of distinct trajectories.

310 For both viruses, we obtain oscillating patterns of π_0 that are consistent with our expectations for antigenic
311 sites evolving under both immune selection and functional constraint. Non-antigenic sites [Figure 7(c) and (d)]
312 generally do not exhibit these fluctuations, but some non-antigenic sites in RSV-A may experience frequency
313 fluctuations due to linkage to antigenic sites [Figure 7(d)]. Patterns of frequency change in H3N2 and RSV-
314 A differ considerably from each other. H3N2 frequencies have sharper and slower oscillations, which are
315 suggestive of both a smaller population size and longer lasting immunity. At least four antigenic sites in H3N2
316 revert and fix at the ancestral state which indicates very strong selective constraint. RSV-A shows more rapid

317 oscillations, suggesting faster decaying immunity and moderate selective constraint. The relatively short time
318 that the ancestral allele is at high frequencies suggests that selective constraint has a smaller influence than
319 for H3N2.

320 4. Discussion

321 We have shown that for acute, recurrent infections, the probability of reversion at antigenic sites depends
322 on the interaction between the cost of immune escape and the duration of host immunity. Similar to models
323 for HIV [17], we find that a higher cost of immune escape increases the probability of antigenic reversion. The
324 impact of the cost of immune escape on the reversion probability is greater when the basic reproductive ratio
325 is low, as small reductions in transmissibility have a more detrimental effect. This is in agreement with a
326 previous study on the effect of selective constraint on antigenic drift [35]. In addition to these two parameters,
327 we find that longer lasting immunity can also reduce the probability of reversion, but the precise extent of this
328 reduction depends on the time between antigenic substitutions.

329 The time between antigenic substitutions, which is inversely proportional to the viral population size and
330 mutation rate, is closely related to the rate of mutational input θ , a parameter commonly used in population
331 genetics to describe the time-scale of selection and drift. In the epidemiological model, it affects the balance
332 between selective constraint and antigenic selection by determining the extent to which prior immunity has
333 decayed. When the interval between antigenic substitutions is small, immunity against the ancestral strain
334 remains high at the time of substitution so that antigenic selection reduces the reversion probability. For larger
335 intervals between antigenic substitutions, prior immunity will have decayed to a greater extent and the basic
336 reproductive ratio and cost of immune escape become stronger determinants of the reversion probability. In the
337 context of phylodynamic models, θ is also the parameter which is used to link the coalescent to epidemiological
338 models [36].

339 Previous studies have described varying levels of reversion in a range of viruses and speculated on the
340 influence of host immunity [5, 2, 8], but it has been unclear how the level of reversion should be quantified
341 and how these results should be interpreted. In contrast to previous studies [5, 37] based on phylogenetic
342 methods, we propose using temporal patterns of frequency change to quantify reversion. Where sequence data
343 from multiple time-points is available, a frequency-based approach can more easily show the time-dependent
344 effect of antigenic selection. Simulation results predict that varying parameters controlling population size,
345 transmission rate, immunity decay and selective constraint have qualitative effects on the frequency of the
346 ancestral allele π_0 which are consistent with the analytical model, providing a means for interpretation. As
347 our approach uses site-frequency data rather than a phylogeny, it is amenable to the application of large
348 time-structured data sets, but is also more sensitive to effects such as biased sampling and spatial structure.

349 In this paper, we compared patterns of π_0 for two viruses that induce acute respiratory infection which
350 recurrently infect human populations and induce long-term immunity: influenza A (H3N2) and RSV-A. For
351 both viruses, we observed fluctuations in frequency at antigenic sites suggesting the presence of both immune

memory and selective constraint. Without the continuously changing balance between these two effects, we would expect an allele for a particular site to reach fixation and remain in that state [27]. While RSV has been reported to experience high levels of reversions [5], previous phylogenetic studies have not identified reversion in H3N2. However, a recent study [8] showed that changes at antigenic sites in H3N2 occur as cycles in a genotype network; that is, mutations to multiple states occur before reversion to the ancestral allele, so that the reversion is not identifiable along a the phylogeny.

Our model suggests that the higher rates of reversion in RSV-A compared to H3N2 is due mainly to more rapidly decaying immunity rather than stronger selective constraint. Fluctuations in frequency are more rapid and complete fixation of the ancestral amino acid does not occur for most antigenic sites of RSV-A. In contrast, for H3N2, we observe multiple occasions where a fixation of the ancestral amino acid occurs, and long periods where $\pi_0 = 1$ is maintained, suggesting strong selective constraints. This is consistent with the location of the sites within the receptor binding region of the HA gene, so that any antigenic change is also likely to affect viral transmissibility [29]. Comparison between the frequency of the oscillations also suggests that H3N2 induces more long-lasting immunity than RSV-A. RSV-A exhibits more rapid fluctuation while several of the antigenic sites in H3N2 were fixed for long periods (> 10 years) at a derived amino acid, supporting the hypothesis that immune pressure against reversion is maintained for long periods. Frequency patterns of H3N2 frequency patterns are consistent with multi-site codon simulations (Figure 5) with host immunity decay rate γ on the order of 10^{-4} , whereas a value of $\gamma \approx 10^{-3}$ is more compatible with frequency patterns for RSV-A. These values are in agreement with reinfection experiments which estimate immunity for H3N2 lasting 8 years ($\gamma = 3 \times 10^{-4} \text{ day}^{-1}$) [38] compared to 1.8 years ($\gamma = 1.5 \times 10^{-3} \text{ day}^{-1}$) for RSV-A [39].

Our study shows that the frequency of the ancestral allele, π_0 , which can be easily calculated for time-stamped viral sequences, is informative about the immune dynamics and cost of escape. In particular, sharp fluctuations in frequency is indicative of immune selection occurring at a comparable time-scale to substitutions at antigenic sites. However, a small number of linked sites may also display similar patterns as they co-segregate with antigenic sites. That is, frequency patterns should not be used as a method to identify antigenic sites; but where the antigenic sites are known, frequency patterns provide information about the epidemiology of the virus as a whole.

The approach outlined here provides a qualitative description rather than estimates of the epidemiological parameters. Analytical expressions, relating the probability of reversion to the parameters underlying the viral dynamics for the three-strain model, rely on the assumption that each strain reaches equilibrium before it is replaced. This assumption tends to be violated when population sizes and mutation rates become large, so that we generally underestimate the probability of reversion. To address the restrictions of the equilibrium assumptions and the assumption of only three strains, we used computer simulations describing sequence dynamics in a multi-site model. Formal inference using a complex computational model is a challenge for future research. Despite the simplicity, our approach is useful in providing a scheme to consider both epidemiological and molecular effects simultaneously. As such, it is complementary to both coalescent approaches [40, 41, 42] which assume epidemiological dynamics are largely unaffected by molecular changes, and to codon-based

389 methods [14, 15] which assume that substitution occurs instantaneously as a time-homogeneous process along
390 branches of the phylogeny.

391 Our model highlights the importance of understanding the interaction between epidemiological and molec-
392 ular effects. The results imply that different evolutionary trajectories are expected in viral populations with
393 the same distribution of fitness effects but differing population size and contact rates. In particular, we expect
394 that viral populations in larger cities with denser populations undergo less reversion and are more likely to
395 generate antigenically novel variants.

396 Acknowledgements

397 We thank Peter White for discussions about reversion in viruses. This work was supported by a Discovery
398 Grant DP110100465 from the Australian Research Council and by the Australian Postgraduate Award to
399 CHSC.

400 References

- 401 [1] B. T. Grenfell, O. G. Pybus, J. R. Gog, J. L. N. Wood, J. M. Daly, J. A. Mumford, E. C. Holmes,
402 Unifying the epidemiological and evolutionary dynamics of pathogens, *Science* 303 (5656) (2004) 327–
403 332. doi:10.1126/science.1090727.
- 404 [2] W. Delport, K. Scheffler, C. Seoighe, Frequent toggling between alternative amino acids is driven by
405 selection in HIV-1, *PLoS Pathog* 4 (12) (2008) e1000242. doi:10.1371/journal.ppat.1000242.
- 406 [3] H. R. Fryer, J. Frater, A. Duda, M. G. Roberts, R. E. Phillips, A. R. McLean, The SPARTAC Trial
407 Investigators, Modelling the evolution and spread of HIV immune escape mutants, *PLoS Pathog* 6 (11)
408 (2010) e1001196. doi:10.1371/journal.ppat.1001196.
- 409 [4] A. J. Leslie, K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes,
410 T. Allen, J. G. Prado, M. Altfeld, C. Brander, C. Dixon, D. Ramduth, P. Jeena, S. A. Thomas, A. S.
411 John, T. A. Roach, B. Kupfer, G. Luzzi, A. Edwards, G. Taylor, H. Lyall, G. Tudor-Williams, V. Novelli,
412 J. Martinez-Picado, P. Kiepiela, B. D. Walker, P. J. R. Goulder, HIV evolution: CTL escape mutation
413 and reversion after transmission, *Nat Med* 10 (3) (2004) 282–289. doi:10.1038/nm992.
- 414 [5] V. F. Botosso, P. M. d. A. Zanotto, M. Ueda, E. Arruda, A. E. Gilio, S. E. Vieira, K. E. Stewien,
415 T. C. T. Peret, L. F. Jamal, M. I. d. M. C. Pardini, J. R. R. Pinho, E. Massad, O. A. Sant’Anna, E. C.
416 Holmes, E. L. Durigon, the VGDN Consortium, Positive selection results in frequent reversible amino
417 acid replacements in the G protein gene of human respiratory syncytial virus, *PLoS Pathog* 5 (1) (2009)
418 e1000254. doi:10.1371/journal.ppat.1000254.

- 419 [6] S. J. Irausquin, A. L. Hughes, Distinctive pattern of sequence polymorphism in the NS3 protein of
420 hepatitis C virus type 1b reflects conflicting evolutionary pressures, *J Gen Virol* 89 (8) (2008) 1921–1929.
421 doi:10.1099/vir.0.2008/000992-0.
- 422 [7] J. R. Bailey, S. Laskey, L. N. Wasilewski, S. Munshaw, L. J. Fanning, E. Kenny-Walsh, S. C. Ray,
423 Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source
424 exposure, *J Virol* 86 (23) (2012) 12582–12590. doi:10.1128/JVI.01440-12.
- 425 [8] A. Wagner, A genotype network reveals homoplastic cycles of convergent evolution in influenza A (H3N2)
426 haemagglutinin, *Proc. R. Soc. B* 281 (1786) (2014) 20132763. doi:10.1098/rspb.2013.2763.
- 427 [9] P. S. Wikramaratna, M. Sandeman, M. Recker, S. Gupta, The antigenic evolution of influenza: drift or
428 thrift?, *Phil. Trans. R. Soc. B* 368 (1614) (2013) 20120200. doi:10.1098/rstb.2012.0200.
- 429 [10] C. R. Parrish, C. F. Aquadro, M. L. Strassheim, J. F. Evermann, J. Y. Sgro, H. O. Mohammed, Rapid
430 antigenic-type replacement and DNA sequence evolution of canine parvovirus., *J Virol* 65 (12) (1991)
431 6544–6552.
- 432 [11] S. M. Lemon, L. N. Binn, R. Marchwicki, P. C. Murphy, L.-H. Ping, R. w. Jansen, L. V. S. Asher, J. T.
433 Stapleton, D. G. Taylor, J. W. LeDuc, In vivo replication and reversion to wild type of a neutralization-
434 resistant antigenic variant of hepatitis A virus, *J Infect Dis.* 161 (1) (1990) 7–13. doi:10.1093/infdis/
435 161.1.7.
- 436 [12] R. Ketterlinus, K. Wieggers, R. Dernick, Revertants of poliovirus escape mutants: new insights into
437 antigenic structures, *Virology* 192 (2) (1993) 525–533. doi:10.1006/viro.1993.1068.
- 438 [13] O. G. Pybus, A. Rambaut, Evolutionary analysis of the dynamics of viral infectious disease, *Nat Rev*
439 *Genet* 10 (8) (2009) 540–550. doi:10.1038/nrg2583.
- 440 [14] R. Nielsen, Z. Yang, Estimating the distribution of selection coefficients from phylogenetic data with
441 applications to mitochondrial and viral DNA, *Mol Biol Evol* 20 (8) (2003) 1231–1239. doi:10.1093/
442 molbev/msg147.
- 443 [15] A. U. Tamuri, M. Dos Reis, R. A. Goldstein, Estimating the distribution of selection coefficients from
444 phylogenetic data using sitewise mutation-selection models, *Genetics* 190 (3) (2012) 1101–1115. doi:
445 10.1534/genetics.111.136432.
- 446 [16] S. L. Kosakovsky-Pond, A. F. Poon, A. J. Leigh Brown, S. D. Frost, A maximum likelihood method for
447 detecting directional evolution in protein sequences and its application to influenza A virus, *Mol Biol Evol*
448 25 (9) (2008) 1809–1824. doi:10.1093/molbev/msn123.
- 449 [17] S. J. Kent, C. S. Fernandez, C. Jane Dale, M. P. Davenport, Reversion of immune escape HIV variants
450 upon transmission: insights into effective viral immunity, *Trends Microbiol* 13 (6) (2005) 243–246. doi:
451 10.1016/j.tim.2005.03.011.

- 452 [18] J. Petravic, L. Loh, S. J. Kent, M. P. Davenport, CD4+ target cell availability determines the dynamics
453 of immune escape and reversion in vivo, *J Virol* 82 (8) (2008) 4091–4101. doi:10.1128/JVI.02552-07.
- 454 [19] J. da Silva, Antibody selection and amino acid reversions, *Evolution* 66 (10) (2012) 3079–3087. doi:
455 10.1111/j.1558-5646.2012.01686.x.
- 456 [20] H. W. Hethcote, The mathematics of infectious diseases, *SIAM Review* 42 (4) (2000) 599–653. doi:
457 10.1137/S0036144500371907.
- 458 [21] J. R. Gog, B. T. Grenfell, Dynamics and selection of many-strain pathogens, *Proc Natl Acad Sci U S A*
459 99 (26) (2002) 17209–17214. doi:10.1073/pnas.252512799.
- 460 [22] M. J. Keeling, P. Rohani, *Modeling infectious diseases in humans and animals*, Princeton University Press,
461 2008.
- 462 [23] M. Kimura, A simple method for estimating evolutionary rates of base substitutions through comparative
463 studies of nucleotide sequences, *J Mol Evol* 16 (2) (1980) 111–120.
- 464 [24] A. L. Lloyd, Estimating variability in models for recurrent epidemics: assessing the use of moment closure
465 techniques, *Theoretical Population Biology* 65 (1) (2004) 49–65. doi:10.1016/j.tpb.2003.07.002.
466 URL <http://linkinghub.elsevier.com/retrieve/pii/S0040580903001175>
- 467 [25] M. J. Keeling, B. T. Grenfell, Disease Extinction and Community Size: Modeling the Persistence of
468 Measles, *Science* 275 (5296) (1997) 65–67. doi:10.1126/science.275.5296.65.
469 URL <http://www.sciencemag.org/content/275/5296/65>
- 470 [26] M. Kimura, On the probability of fixation of mutant genes in a population, *Genetics* 47 (6) (1962) 713–719.
- 471 [27] L. Zhao, M. Lascoux, A. D. J. Overall, D. Waxman, The characteristic trajectory of a fixing allele:
472 A consequence of fictitious selection that arises from conditioning, *Genetics* 195 (3) (2013) 993–1006.
473 doi:10.1534/genetics.113.156059.
- 474 [28] Y. Bao, P. Bolotov, D. Dernovoy, B. Kiryutin, L. Zaslavsky, T. Tatusova, J. Ostell, D. Lipman, The
475 influenza virus resource at the National Center for Biotechnology Information, *J. Virol.* 82 (2) (2008)
476 596–601. doi:10.1128/JVI.02005-07.
- 477 [29] B. F. Koel, D. F. Burke, T. M. Bestebroer, S. v. d. Vliet, G. C. M. Zondag, G. Vervaet, E. Skepner,
478 N. S. Lewis, M. I. J. Spronken, C. A. Russell, M. Y. Eropkin, A. C. Hurt, I. G. Barr, J. C. d. Jong, G. F.
479 Rimmelzwaan, A. D. M. E. Osterhaus, R. A. M. Fouchier, D. J. Smith, Substitutions near the receptor
480 binding site determine major antigenic change during influenza virus evolution, *Science* 342 (6161) (2013)
481 976–979. doi:10.1126/science.1244730.

- 482 [30] D. J. Smith, A. S. Lapedes, J. C. de Jong, T. M. Bestebroer, G. F. Rimmelzwaan, A. D. M. E. Osterhaus,
483 R. A. M. Fouchier, Mapping the antigenic and genetic evolution of influenza virus, *Science* 305 (5682)
484 (2004) 371–376. doi:10.1126/science.1097211.
- 485 [31] I. Martínez, J. Dopazo, J. A. Melero, Antigenic structure of the human respiratory syncytial virus G
486 glycoprotein and relevance of hypermutation events for the generation of antigenic variants., *J Gen Virol*
487 78 (10) (1997) 2419–2429.
- 488 [32] O. García, M. Martín, J. Dopazo, J. Arbiza, S. Frabasile, J. Russi, M. Hortal, P. Perez-Breña, I. Martínez,
489 B. García-Barreno, Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating
490 lineages and correlation of genetic and antigenic changes in the G glycoprotein., *J Virol* 68 (9) (1994)
491 5448–5459.
- 492 [33] K. T. Zlateva, P. Lemey, A.-M. Vandamme, M. V. Ranst, Molecular evolution and circulation patterns of
493 human respiratory syncytial virus subgroup A: Positively selected sites in the attachment G glycoprotein,
494 *J Virol* 78 (9) (2004) 4675–4683. doi:10.1128/JVI.78.9.4675-4683.2004.
- 495 [34] M. A. Pretorius, S. v. Niekerk, S. Tempia, J. Moyes, C. Cohen, S. A. Madhi, M. Venter, Replacement and
496 positive evolution of subtype A and B respiratory syncytial virus G-protein genotypes from 1997–2012 in
497 South Africa, *J Infect Dis.* 208 (suppl 3) (2013) S227–S237. doi:10.1093/infdis/jit477.
- 498 [35] A. Kucharski, J. R. Gog, Influenza emergence in the face of evolutionary constraints, *P Roy Soc B: Biol*
499 *Sci* doi:10.1098/rspb.2011.1168.
- 500 [36] K. Koelle, D. A. Rasmussen, Rates of coalescence for common epidemiological models at equilibrium, *J*
501 *R Soc Interface* 9 (70) (2012) 997–1007. doi:10.1098/rsif.2011.0495.
- 502 [37] D. Palmer, J. Frater, R. Phillips, A. R. McLean, G. McVean, Integrating genealogical and dynamical
503 modelling to infer escape and reversion rates in HIV epitopes, *Proc. R. Soc. B* 280 (1762) (2013) 20130696.
504 doi:10.1098/rspb.2013.0696.
- 505 [38] R. B. Couch, J. A. Kasel, Immunity to influenza in man, *Annual Reviews in Microbiology* 37 (1) (1983)
506 529–549.
- 507 [39] C. B. Hall, E. E. Walsh, C. E. Long, K. C. Schnabel, Immunity to and frequency of reinfection with
508 respiratory syncytial virus, *J Infect Dis.* 163 (4) (1991) 693–698. doi:10.1093/infdis/163.4.693.
- 509 [40] T. Stadler, S. Bonhoeffer, Uncovering epidemiological dynamics in heterogeneous host populations using
510 phylogenetic methods, *Phil. Trans. R. Soc. B* 368 (1614). doi:10.1098/rstb.2012.0198.
- 511 [41] S. D. W. Frost, E. M. Volz, Viral phylodynamics and the search for an ‘effective number of infections’,
512 *Philos T Roy Soc B* 365 (1548) (2010) 1879–1890. doi:10.1098/rstb.2010.0060.

- 513 [42] S. D. W. Frost, E. M. Volz, Modelling tree shape and structure in viral phylodynamics, *Phil. Trans. R.*
514 *Soc. B* 368 (1614). doi:10.1098/rstb.2012.0208.
- 515 [43] K. Koelle, M. Kamradt, M. Pascual, Understanding the dynamics of rapidly evolving pathogens through
516 modeling the tempo of antigenic change: Influenza as a case study, *Epidemics* 1 (2) (2009) 129–137.
517 doi:10.1016/j.epidem.2009.05.003.
- 518 [44] G. Katriel, The size of epidemics in populations with heterogeneous susceptibility, *J Math Biol*doi:
519 10.1007/s00285-011-0460-2.

Table 1: Table of parameters used in the multi-site simulation model.

Parameter	Description
β	Transmission rate per time-step
δ	Recovery rate per time-step
γ	Decay rate of host immunity per time-step
σ	Strength of immune protection
μ	Mutation rate per site per time-step
s	Cost of immune escape
L_a	Number of antigenic sites
N	Host population size




Figure 1: An example of forward substitution [panels (a) and (c)] and reversion [panels (b) and (d)] in the two-site bit-string epidemiological model. Solid lines show the trajectory from a single simulation of the number of hosts [panels (a) and (b)] infected by, and the proportion of hosts susceptible [panels (c) and (d)] to strains 0, 1 and 2. Simulations are initialised with a small number of hosts infected with strain 0 which tend towards the equilibrium [horizontal grey dashed lines; Equations (5–6)]. At time t_1 , strain 1 emerges and dominates the population until time t_2 when a third strain (either strain 0 or 2) emerges. Times t_1 and t_2 are indicated by vertical dotted grey lines. Between t_2 and t_1 , the expected proportion of susceptible hosts [Equations (12–15)] is shown by dashed lines. Simulations were run with parameters (a) $\beta = 1.0 \text{ day}^{-1}$ and (b) $\beta = 0.6 \text{ day}^{-1}$ and in both panels, $N = 10^4$, $\delta = 0.2$, $\gamma = 10^{-3} \text{ day}^{-1}$ and $s = 0.1$.




Figure 2: The probability of reversion, as a function of the time between strain emergence τ . The blue line shows the reversion probability [Equation (19)] of an unconstrained antigenic site as immunity decays, whereas the green ($s = 0.1$) and red ($s = 0.2$) lines show the combined effect of selective cost and immunity. Points show the proportion of reversion events observed from simulations of the two-site bit-string model. The proportion was computed from the binned number of substitution events that occurred immediately after a transition from strain 0 to strain 1, using the observed time between antigenic substitutions as a proxy for τ . Simulations were run for 10^5 time-steps, with a time-step of one day, with 1000 replicates for each parameter combination of s and N . All other parameters were set to immune decay: $\gamma = 10^{-3} \text{ day}^{-1}$, mutation rate: $\mu = 10^{-5} \text{ site}^{-1} \text{ day}^{-1}$, recovery rate: $\delta = 0.2 \text{ day}^{-1}$ and transmission rate: $\beta = 0.6 \text{ day}^{-1}$.




Figure 3: A comparison of the sensitivity of the reversion probability [Equation (19)] to the strength of immunity σ for different (a) rates of recovery δ and (b) rates of immunity decay γ . Unless otherwise specified, parameters were set to $\gamma = 10^{-3} \text{ day}^{-1}$, $\delta = 0.1 \text{ day}^{-1}$, $\beta/\delta = 5$, $\gamma\tau = 0.5$ and $\mu = 10^{-5} \text{ site}^{-1} \text{ day}^{-1}$.




Figure 4: The effect of the cost of immune escape s and decay rate of immunity γ on the probability of reversion [Equation (19)]. In (a), we hold the level of immunity ($\gamma\tau = 0.5$) constant to show how varying basic reproductive ratio β/δ changes the effect of s . In (b), we show the effect of varying s for different values of γ with a fixed time between strain emergence $\tau = 3 \times 365$ days and $\beta/\delta = 5$. Other parameters were set to $\delta = 0.2 \text{ day}^{-1}$ and $\mu = 10^{-5} \text{ site}^{-1} \text{ day}^{-1}$.




Figure 5: The effect of population size and duration of immunity on the frequency of the ancestral allele π_0 at antigenic sites under selective constraint ($s = 0.2$). Each line represents the changing frequencies, at a single antigenic site, of the ancestral allele estimated to be the earliest sampled amino acid residue after the burn-in period (1000 days). For high rates of mutational input [panels (d) and (f)], the earliest sequence may not be the true ancestral sequence (set to be the most transmissible), which in some cases results in low observed values of π_0 . Each panel represents the dynamics of a single simulation, with π_0 computed from samples of 20 sequences taken every 200 days. All simulations were run with a time-step of one day and parameters $\beta = 1.0 \text{ day}^{-1}$, $\delta = 0.2 \text{ day}^{-1}$, $\mu = 10^{-5} \text{ site}^{-1} \text{ day}^{-1}$, $L_a = 7$, to match parameters used for human influenza A (H3N2) [43].




Figure 6: The frequency of the the ancestral allele π_0 at antigenic sites under no selective constraint ($s = 0$). Lines in each panel show the changing frequency of the ancestral (earliest sampled) allele at each antigenic site in a single simulation. π_0 was computed from samples of 20 sequences taken every 200 days, discarding all sequence data from the burn-in period of 1000 days. All simulations were run with $\gamma = 1 \times 10^{-3} \text{ day}^{-1}$, $\beta = 1.0 \text{ day}^{-1}$, $\delta = 0.2 \text{ day}^{-1}$, $\mu = 10^{-5} \text{ site}^{-1} \text{ day}^{-1}$, and $L_a = 7$.




Figure 7: Trajectory of the frequency of the ancestral allele π_0 computed at antigenic sites of (a) human H3N2 and (b) human RSV-A show fluctuations which are distinct from randomly chosen non-antigenic sites [panels (c) and (d)]. Frequencies were computed at (a, c) seven sites in the HA segment of H3N2 with A/Aichi/2/1968 as the ancestral strain, and (b, d) eight sites in the C-terminal hyper-variable region of the surface G protein of RSV-A using strain AF065406 (sampled in 1981) as the ancestral strain. Sequences were pooled according to the year of isolation, with years in which fewer than five sequences were sampled were excluded.

520 **Appendix A. Comparison of the compartmental SIRS model with an agent-based model for a**
521 **single strain**

522 The compartmental SIRS model described in Section 2.1 tracks only the number of hosts with immunity
523 in the population R , which is increased with each infection by an increment of σ . The model, however, does
524 not account for the fact that partially immune hosts which are re-infected cannot gain more than complete
525 immunity. To examine the effect of this approximation, we implement, for the single strain case, an agent-
526 based model which tracks the level of immunity $r_i \in [0, 1]$ in each host i in the population. The agent-based
527 variables can be related to the population model [Equation (3)] by summing across all uninfected hosts \tilde{I} ,

$$\sum_{i \in \tilde{I}} r_i = \sigma R.$$

528 We implement two agent-based simulations which differ in how they model the decay of host immunity. In
529 model A1, immunity decays deterministically, so there is no variability in the rate of decay between hosts. In
530 contrast, in model A2, we maximise the variability in the rate of decay by having complete loss of immunity
531 in a proportion of hosts. In both models, population-wide levels of immunity are reduced, but there are
532 considerable differences in the variation in levels of immunity between hosts, which is known to affect the
533 epidemiological dynamics [44].

- 534 1. Transmission : The number of new infections in each time-step is Poisson with mean $\beta SI/N$. Newly
535 infected hosts are randomly drawn with the set of uninfected hosts by multinomial sampling, according
536 to $1 - r_i$. Note that their immunity status is not altered on infection, so they retain immunity obtained
537 from prior infections, but their contribution is not included into the population variable R .
- 538 2. Recovery: The number of infected hosts which recover in each time-step is Poisson with mean δI trun-
539 cated with an upper bound of $I - 1$. Each recovered host i is drawn from the infected population with
540 uniform probability and their immunity is increased by

$$r_i := \min(1, r_i + \sigma). \tag{A.1}$$

- 541 3. Decay of host immunity is simulated differently between models A1 and A2. In model A1, immunity is
542 reduced deterministically in each uninfected hosts i

$$r_i := r_i(1 - \gamma), \tag{A.2}$$

543 whereas in model A2,

$$r_i := r_i(1 - U), \text{ where } U \sim \text{Bernoulli}(\gamma). \tag{A.3}$$

544 We compare the agent-based models to the compartmental model implemented in Section 2.2 with no mutation
545 (single-strain). Importantly, the equilibrium value for S is largely unchanged between models [Figure A.8(b)],




Figure A.8: Comparison of the simulation dynamics between agent-based and compartmental simulations. Shaded areas show the interquartile range for 100 replicates with $\beta = 0.6 \text{ day}^{-1}$, $\delta = 0.2 \text{ day}^{-1}$, $\gamma = 10^{-3} \text{ day}^{-1}$, $\sigma = 0.8$, $N = 10^3$.




Figure A.9: Underestimation of the size of the infected population in the compartmental model compared to the agent-based models (a) A1 with gradual decay of host-immunity and (b) A2 with sudden decay of host-immunity. The extent of underestimation was computed by taking the mean of $I(t)$ over 100 simulations over 10^4 time-steps for both the compartmental model and the agent-based model, and taking the ratio of the means. Simulations were run with $\delta = 0.2 \text{ day}^{-1}$ and $\gamma = 10^{-3} \text{ day}^{-1}$.

546 suggesting that derivations of $\rho(\tau)$ remain valid. However, differences can be seen in equilibrium value of I .
 547 The compartmental model equilibrates at a lower mean value of I compared to both agent-based models A1
 548 and A2, with a larger difference when compared to A1 (Figure A.9). However, this discrepancy is comparable
 549 to the variance in the of $I(t)$ over time [Figure A.8(a)]. The difference in I between simulations is largely
 550 unaffected by changes in population size N or transmission rate β , but mainly influenced by σ (Figure A.9).




Figure B.10: The probability of reversion, as function of the time between strain emergence τ . This is the same as Figure 2, except that substitution events which occur before the population reaches equilibrium are ignored.

551 Appendix B. Effect of equilibrium assumption in SIRS model

552 The derivation of the probability of reversion [Equation (19)] depends heavily on the assumption that the
553 system reaches equilibrium before antigenic substitutions occur. This effect can be seen by comparing Figure
554 2 to Figure B.10 where substitution events that occur before equilibrium is reached are ignored. The points
555 with the greatest discrepancy to the theoretical values of $\rho(\tau)$ for intermediate values of τ are not seen in
556 Figure B.10. There is more variation from theoretical expectations for large τ , as more substitution events
557 have been removed the calculation.